| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4862383
Max Phase: Preclinical
Molecular Formula: C16H17ClFN3O
Molecular Weight: 321.78
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: O=C(NC1CCNCC1)c1ccc(-c2ccc(Cl)c(F)c2)[nH]1
Standard InChI: InChI=1S/C16H17ClFN3O/c17-12-2-1-10(9-13(12)18)14-3-4-15(21-14)16(22)20-11-5-7-19-8-6-11/h1-4,9,11,19,21H,5-8H2,(H,20,22)
Standard InChI Key: XLYOHELABQVCEL-UHFFFAOYSA-N
Associated Targets(Human)
TZM 838 Activities
Associated Targets(non-human)
Envelope glycoprotein gp160 755 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 321.78 | Molecular Weight (Monoisotopic): 321.1044 | AlogP: 2.96 | #Rotatable Bonds: 3 |
| Polar Surface Area: 56.92 | Molecular Species: BASE | HBA: 2 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 10.03 | CX LogP: 2.01 | CX LogD: -0.53 |
| Aromatic Rings: 2 | Heavy Atoms: 22 | QED Weighted: 0.81 | Np Likeness Score: -1.35 |
References
| 1. Iusupov IR, Curreli F, Spiridonov EA, Markov PO, Ahmed S, Belov DS, Manasova EV, Altieri A, Kurkin AV, Debnath AK.. (2021) Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements., 224 [PMID:34246921] [10.1016/j.ejmech.2021.113681] |
Source
Source(1):